Dendrite Launches Mobile Operating Environment for Pharmaceutical Sales Force Effectiveness; Wireless Operating Environment Ena
June 05 2006 - 8:00AM
Business Wire
Dendrite International, Inc., (NASDAQ:DRTE) a leading provider of
pharmaceutical industry solutions, today announced the launch of
j-ForceWIRELESS(TM), the first wireless operating environment
designed to provide pharmaceutical sales forces in developing
countries with a turnkey sales force effectiveness solution. The
solution will be introduced in China, one of the fastest growing
pharmaceutical markets in the world, in July, 2006. "While the US
market continues to see the personal computer as the central tool
for business applications, developing nations are far more inclined
to rely on mobile devices," said Dendrite Chairman and CEO John
Bailye. "With the release of this solution, we are bringing many of
the capabilities to emerging nations that U.S. sales forces take
for granted. This release provides pharmaceutical companies the
ability to maximize productivity of their sales forces."
j-ForceWIRELESS rests on a secure, proprietary server, and is
simply downloaded by the sales representative onto any web-enabled
handset. Since the application is used in an off-line mode, the
representative is neither dependent on continuous wireless coverage
nor susceptible to escalating data charges. Using the solution,
sales representatives can record daily activities to their mobile
phones, exchange data with the head office for direction or
reporting, and issue alerts. "Dendrite has already deployed PDA and
Smartphone based solutions in emerging markets, however,
j-ForceWIRELESS takes our mobile-computing initiatives to next
level," said Jean-Paul Modde, president Dendrite Asia Pacific. "It
compliments our current solution suite and provides the ultimate
flexibility in achieving sales force effectiveness. We are
committed to continuously developing innovative and value-add
solutions for the fastest growing economy in the world." About
Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE)
enables sales, marketing, clinical and compliance solutions for the
global, pharmaceutical industry. The Company's clients are located
in more than 50 countries and include the world's top 20
pharmaceutical companies. For more information, please visit
www.dendrite.com. Note: Dendrite is a registered trademark of
Dendrite International, Inc. This document may contain
forward-looking statements that may be identified by such
forward-looking terminology as "expect," "believe," "anticipate,"
"will," "intend," "plan," "target," "outlook," "guidance," and
similar statements or variations. Such forward-looking statements
are based on our current expectations, estimates, assumptions and
projections and involve significant risks and uncertainties,
including risks which may result from our dependence on the
pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our
solutions; our fixed expenses in relation to fluctuating revenues
and variations in customers' budget cycles; dependence on certain
major customers; changes in demand for our products and services
attributable to any weakness experienced in the economy or mergers,
acquisitions and consolidations in the pharmaceutical industry;
successful and timely development and introduction of new products
and versions; rapid technological changes; increased competition;
international operations; integrating the entities we acquire; our
ability to effectively manage our growth; the protection of our
proprietary technology; our ability to compete in the
Internet-related products and services market; the continued demand
for Internet-related products and services; the ability of our
third party vendors to respond to technological change; our ability
to maintain our relationships with third-party vendors; less
favorable than anticipated results from strategic relationships;
dependence of data solutions on strategic relationships; events
which may affect the U.S. and world economies; and catastrophic
events which could negatively affect our information technology
infrastructure. Other important factors that should be reviewed and
carefully considered are included in the company's 10-K, 10-Qs, and
other reports filed with the SEC. Actual results may differ
materially. The company assumes no obligation for updating any such
forward-looking statements to reflect actual results, changes in
assumptions or other changes affecting such forward-looking
statements.
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Aug 2023 to Aug 2024